Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Drugs in Development News & Deals for Alter Brand of Spironolactone

    Client Email Product

    Alter Brand of Spironolactone

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    28
    US DMFs Filed

    US DMFs Filed

    17
    CEP/COS Certifications

    CEP/COS Certifications

    9
    JDMFs Filed

    JDMFs Filed

    4
    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    12
    API REF. PRICE (USD / KG)
    290

    API Market Place

    24
    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    65
    Europe

    Europe

    49
    Canada

    Canada

    13
    Australia

    Australia

    9
    South Africa

    South Africa

    8
    Uploaded Dossiers

    Uploaded Dossiers

    32
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    659.00

    Annual Reports

    0

    FDF Market Place

    16
    EXCIPIENTS
    277
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    10

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    16
    REF STANDARD

    EDQM

    3

    USP

    2

    JP

    4

    Other Listed Suppliers

    7
    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - 100MG
    • TABLET;ORAL - 25MG
    • TABLET;ORAL - 50MG
    • TABLET;ORAL - 25MG;25MG
    • TABLET;ORAL - 50MG;50MG
    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of...

    Details:

    Under the terms of the CRADA, the NCI will serve as sponsor for any clinical trials mutually approved by both parties to study Actimab-A (lintuzumab-Ac225) while Actinium will be responsible for supplying and distributing Actimab-A.


    Lead Product(s): Lintuzumab-ac225,Spironolactone

    Therapeutic Area: Oncology Product Name: Actimab-A

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: National Cancer Institute

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement February 06, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    EUROAPI Spironolactone

    Access Virtual Booth

    Contact Supplier

    View Presentation

    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search